Vergelijking
DSIP vs. Goserelin
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Onderzoek (overig)
Onderzoek (overig)
CAS-nr.
62568-57-4
65807-02-5
Molecuulmassa
848.81 g/mol
1269.43 g/mol
Halfwaardetijd
0.1 h
4.2 h
Sequentie
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GlupGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Azgly-NH2Werkingsmechanisme
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Goserelin
As a GnRH agonist, goserelin binds to the GnRH receptors of the pituitary gland. Initial stimulation transiently raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH). With continuous receptor occupancy, however, the receptors become desensitized and down-regulated, which reduces LH and FSH secretion and consequently the production of testosterone or estrogen. This mechanistic relationship is documented in the pharmacological literature.
Bewijsbasis
Hoogste bewijs
Humane studie
Humane RCT
Studies
4
4
waarvan bij mensen
1
4
Geregistreerde effecten
3
3
Openstaande tegenstrijdigheden
1
1
Gedocumenteerde bijwerkingen
1
2
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between DSIP and Goserelin?
- DSIP is classified as "Onderzoek (overig)", while Goserelin is classified as "Onderzoek (overig)". DSIP: Synthetic nonapeptide isolated in 1977 by Guido Monnier and Marcel Schoenenberger from the blood of rabbits in delta sleep. Despite the name, the role in sleep regulation is contested and not confirmed by Western RCTs in larger populations. Goserelin: Goserelin is a synthetic decapeptide and an agonist of gonadotropin-releasing hormone (GnRH). The medical literature describes it as a hormonal agent that suppresses the release of sex hormones through sustained receptor stimulation. Regulatory-approved indications include prostate cancer, advanced breast cancer, endometriosis, and endometrial thinning, among others. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, DSIP or Goserelin?
- The highest available evidence level is "Humane studie" for DSIP and "Humane RCT" for Goserelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of DSIP and Goserelin in Germany and the United States?
- Duitsland: DSIP — Niet goedgekeurd, Goserelin — Op recept. Verenigde Staten: DSIP — Niet goedgekeurd, Goserelin — Op recept. These are factual summaries with source and review date on the individual pages.